OVERVIEW

The Evolving Treatment Landscape for Metastatic Castration-Resistant Prostate Cancer is organized by Rockpointe and Potomac Center for Medical Education and would be held during Nov 15, 2016 - Nov 15, 2017. This activity is intended for community-based urologists, medical oncologists, surgical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment and care of patients with metastatic castration-resistant prostate cancer (mCRPC).

Community-based clinicians are challenged to stay up to date with the rapidly diversifying treatment landscape for metastatic castration-resistant prostate cancer (mCRPC). Personalized treatment options are dependent on many factors, including knowledge of prior therapy, presence of resistance markers, bone metastases, and patient preferences. This activity will utilize clinical scenarios to demonstrate how to maximize clinical benefit by incorporating current and emerging data into practice and will provide resources to empower patients in treatment decisions.

Educational Objectives :

At the conclusion of this activity, participants should be able to demonstrate the ability to:

• Review the current and emerging data regarding diagnosis and management of mCRPC
• Discuss updated guidelines for systemic therapy and survivorship care planning
• Assess the safety and efficacy data of available therapies and the roles of biomarkers in personalizing the management of mCRPC
• Empower patients to become active participants in their treatment decisions and health management.